{
 "context": "The following article called 'Pacific Life Re Australia Receives Regulatory Approval to Commence Writing Reinsurance Business' was published on 2015-08-18. The body of the article is as follows:\n    \nTuesday, August 18, 2015 11:36AM IST (6:06AM GMT) Pacific Life Re Australia Receives Regulatory Approval to Commence Writing Reinsurance Business Sydney, Australia Pacific Life Re (Australia) Pty Limited (\u201cPacific Life Re Australia\u201d) has received regulatory approval from the Australian Prudential Regulatory Authority (APRA) to commence writing life reinsurance business in Australia. Pacific Life Re Australia is part of Pacific Life Re, the reinsurance division of the Pacific Life group. Pacific Life Re has existing offices in Europe, Asia and North America. The ultimate parent is Pacific Mutual Holding Company, a US-based mutual life insurance company founded in 1868 with over US$137bn in Company Assets. \u201cThis is a significant milestone as we look to bring additional reinsurance capacity to the Australian life market\u201d, says Andrew Gill, Managing Director of Pacific Life Re Australia. \u201cThe Australian market has undergone a fair amount of disruption in the life insurance space over the last few years so we see this as a unique opportunity to bring a fresh approach to supporting Australian insurers.\u201d Pacific Life Re Division CEO, Dave Howell, also commented, \u201cThis licence represents a further expansion of the global Pacific Life Re brand and proposition. We have recruited a very experienced local management team and are looking forward to partnering with our clients in Australia over the coming years.\u201d Pacific Life Re Australia has received a stand-alone financial strength credit rating from S&P of A+ (stable outlook).\n\n    The day before the article was published, the stock price of Akari Therapeutics Plc was 6.099999904632568 and the day after the article was published, the stock price of Akari Therapeutics Plc was ",
 "expected": "39.54999923706055",
 "date": "2015-08-18",
 "ticker": "AKTX",
 "company": "Akari Therapeutics Plc"
}